Announcement on Cancelling Some Special Accounts for Raised Funds
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
View Attachment
Announcement on Cancelling Some Special Accounts for Raised Funds
Filed with SSE ·
6ix hasn’t read this filing yet.
Suzhou Zelgen Biopharmaceuticals Co. Ltd. on 6ix
Earlier from Suzhou Zelgen Biopharmaceuticals
- Announcement on Postponement of Some Investment Projects Financed by Raised Funds
- Announcement on Voluntary Disclosure of Clinical Study Progress of ZG005 for Injection
- Announcement on Voluntary Disclosure of Clinical Study Progress of ZG006 for Injection
- Announcement on Attending the 2024 Semi-annual Collective Performance Briefing for Pharmaceutical and Biological Products Companies on STAR Market
- Announcement on Resolutions of the 15th Meeting of the 2nd Board of Supervisors
Later from Suzhou Zelgen Biopharmaceuticals
- Announcement on Convening the Q3 2024 Performance Briefing
- Announcement on Voluntary Disclosure of Inclusion of Recombinant Human Thrombin into the Catalogue Of Drugs For Basic National Medical Insurance in 2024
- Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trials of Combination of Injectable ZG005 with Gecacitinib Hydrochloride Tablets
- Annual Earnings Preannouncement for 2024
- Indicative Announcement on the Renewal of Concerted Action Agreement and Changes in Equity by Actual Controllers
Follow Suzhou Zelgen Biopharmaceuticals into a list and get an email when it puts out news.
Follow Suzhou Zelgen Biopharmaceuticals